NCT04346654 - A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

September 22, 2023

Study Completion Date

September 22, 2023

Conditions

Immune Thrombocytopenia (ITP)

Interventions

DRUG

Eltrombopag

Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.

DRUG

Dexamethasone

Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.

Trial Locations (10)

Novartis Investigative Site, Kiel

Novartis Investigative Site, Dortmund

Novartis Investigative Site, Aachen

Novartis Investigative Site, Frankfurt

Novartis Investigative Site, Aschaffenburg

Novartis Investigative Site, Donauwörth

Novartis Investigative Site, Kronach

Novartis Investigative Site, Chemnitz

Novartis Investigative Site, Dresden

Novartis Investigative Site, Jena